Drug Trial Radar · NCT01788046
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Last checked: Nov 20, 2026Latest source record: Aug 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
515
Actual
Start
Mar 12, 2013
Primary completion
Apr 14, 2014
Study completion May 9, 2014
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.
Conditions
- Hyperparathyroidism, Secondary
Interventions
EtelcalcetideDrug
Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
PlaceboDrug
Administered intravenously (IV) three times per week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment PhaseTime frame: Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).
Locations
106 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Mobile, Alabama
Research Site
Azusa, California
Research Site
Beverly Hills, California
Research Site
Chula Vista, California
Research Site
Fairfield, California
Research Site
Glendale, California
Research Site
Los Angeles, California
Research Site
Northridge, California
Research Site
Norwalk, California
Research Site
Riverside, California
Research Site
Simi Valley, California
Research Site
Denver, Colorado
Research Site
Stamford, Connecticut
Research Site
Lauderdale Lakes, Florida
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Augusta, Georgia
Research Site
Macon, Georgia
Research Site
Chicago, Illinois
Research Site
Gurnee, Illinois
Research Site
Merrillville, Indiana
Research Site
Wichita, Kansas
Research Site
Shreveport, Louisiana
Research Site
Bethesda, Maryland
Research Site
Ft. Washington, Maryland
Research Site
Detroit, Michigan
Research Site
Brookhaven, Mississippi
Research Site
Lincoln, Nebraska
Research Site
Las Vegas, Nevada
Research Site
Eatontown, New Jersey
Research Site
Brooklyn, New York
Research Site
Fresh Meadows, New York
Research Site
Great Neck, New York
Research Site
Charlotte, North Carolina
Research Site
New Bern, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Columbia, South Carolina
Research Site
Chattanooga, Tennessee
Research Site
Knoxville, Tennessee
Research Site
Arlington, Texas
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.